Neuromuscular blocking agents (NMBAs) are essential drugs in anesthesia and critical care, used to induce muscle relaxation by blocking nerve transmission at the neuromuscular junction.
These agents play a crucial role in procedures where immobilization is essential, such as endotracheal intubation, mechanical ventilation, and complex surgeries.
This article explores the primary types of neuromuscular blocking agents, detailing their mechanisms, clinical uses, and important considerations for safe and effective use.
Take our free course to learn essential pharmacology tips, insights, and strategies to pass the TMC Exam on your first (or next) attempt.
What are Neuromuscular Blocking Agents?
Neuromuscular blocking agents (NMBAs) are a class of drugs that prevent nerve impulses from reaching muscles, effectively causing temporary paralysis of the skeletal muscles.
These agents are commonly used during surgeries and in critical care settings to facilitate intubation and mechanical ventilation, ensure muscle relaxation, and improve surgical conditions.
Mechanism of Action
NMBAs block the transmission of nerve impulses at the neuromuscular junction by interfering with acetylcholine, which prevents muscle contraction. This results in muscle paralysis, allowing for surgical procedures or ventilation without involuntary movements.
Clinical Uses
- Facilitation of intubation: Ensures relaxed airway muscles for easier insertion of the endotracheal tube.
- Surgical procedures: Provides muscle relaxation to improve surgical conditions.
- Mechanical ventilation: Reduces oxygen consumption by preventing spontaneous muscle movements.
- Treatment of certain medical conditions: Used to control muscle spasms in cases like tetanus or status epilepticus.
Considerations and Side Effects
- Monitoring: Proper monitoring is essential to ensure the appropriate level of muscle relaxation and avoid prolonged paralysis.
- Side effects: These can include changes in heart rate, blood pressure, and rare but serious conditions like malignant hyperthermia (particularly with depolarizing agents like succinylcholine).
- Reversal agents: Non-depolarizing NMBAs can be reversed using drugs like neostigmine or sugammadex to restore muscle function after surgery or treatment.
Note: These agents play a critical role in modern anesthesia and intensive care but require careful administration and monitoring due to their powerful effects.
Types of Neuromuscular Blocking Agents
Neuromuscular blocking agents can be classified into two main types:
- Depolarizing agents
- Non-depolarizing agents
Watch this video and keep reading to learn more about the primary types of neuromuscular blocking agents and their uses.
Depolarizing Agents
Depolarizing agents are a type of neuromuscular blocking agent that mimic the action of acetylcholine, a natural neurotransmitter at the neuromuscular junction. These agents bind to acetylcholine receptors on the muscle end plate, causing an initial depolarization that results in a brief muscle contraction.
However, unlike acetylcholine, depolarizing agents are not rapidly broken down by acetylcholinesterase, so the muscle remains depolarized and unresponsive to further stimulation. This leads to sustained muscle relaxation and paralysis.
Example:
Succinylcholine is the most commonly used depolarizing agent, known for its rapid onset and short duration of action, making it ideal for procedures that require quick muscle relaxation, such as intubation.
Characteristics:
- Onset and Duration: Very rapid onset (30–60 seconds) with a short duration (5–10 minutes).
- Clinical Use: Often used to facilitate rapid-sequence intubation or short procedures that require muscle relaxation.
- Side Effects: May cause muscle fasciculations, hyperkalemia, and, in rare instances, malignant hyperthermia.
Note: These characteristics make depolarizing agents valuable in settings that demand immediate muscle relaxation, but their use requires careful monitoring to avoid potential complications.
Non-Depolarizing Agents
Non-depolarizing agents are neuromuscular blocking agents that act as competitive antagonists to acetylcholine at the neuromuscular junction. Unlike depolarizing agents, these drugs do not cause an initial muscle contraction.
Instead, they block the binding of acetylcholine to its receptors on the muscle end plate, preventing depolarization and subsequent muscle contraction. This leads to muscle relaxation and paralysis without the initial depolarization phase.
Examples:
Common non-depolarizing agents include:
- Cisatracurium (Nimbex)
- Pancuronium (Pavulon)
- Rapacuronium (Raplon)
- Mivacurium (Mivacron)
- Atracurium (Tracrium)
- Vecuronium (Norcuron)
- Rocuronium (Zemuron)
Note: These agents vary in their onset time and duration of action, allowing for flexibility in clinical use.
Characteristics:
- Onset and Duration: Onset and duration can vary, with some agents acting rapidly and others more slowly. Rocuronium, for example, has a relatively fast onset, while pancuronium has a longer duration of action.
- Clinical Use: Non-depolarizing agents are often used during longer surgical procedures and in critical care settings where extended muscle relaxation is needed.
- Reversibility: The effects of non-depolarizing agents can be reversed using acetylcholinesterase inhibitors like neostigmine or with specific reversal agents such as sugammadex (for rocuronium and vecuronium).
Note: Non-depolarizing agents are preferred when controlled and sustained muscle relaxation is necessary, as they provide a wider range of options for onset and duration. Their reversible nature allows for more precise control over the length of muscle paralysis.
Neuromuscular Blocking Agent Practice Questions
1. What are two types of skeletal muscle relaxants?
Neuromuscular blocking agents and spasmolytic drugs.
2. What is the major difference between the two types of blocking agents?
Neuromuscular blocking agents act outside the central nervous system (CNS), while spasmolytic drugs primarily act within the CNS and are often used to treat spasticity disorders originating from CNS issues.
3. What is the mechanism of action for neuromuscular blocking agents?
They interfere with neurotransmission at the neuromuscular junction, lack central nervous system activity, and are primarily used as adjuncts in general anesthesia during surgery.
4. What do pre-ganglionic autonomic neurons and somatic neurons have in common?
Both use acetylcholine as their neurotransmitter.
5. Why does pancuronium have associated adverse effects on the autonomic nervous system (ANS)?
Due to the similarity in neurotransmitter usage and associated nicotinic receptors.
6. What is the result of prolonged occupation of a nicotinic receptor by an agonist, and what is this called?
It leads to a depolarizing blockade, where persistent depolarization causes sodium inactivation gates to remain closed, resulting in muscle paralysis. This state is known as accommodation. Eventually, the muscle repolarizes but becomes desensitized to the agonist.
7. What is a general characteristic of neuromuscular blocking agents?
They are structural analogs of acetylcholine.
8. What are the two types of neuromuscular blocking agents and their mechanisms of action?
Non-depolarizing agents: nicotinic receptor antagonists. Depolarizing agents: nicotinic receptor agonists.
9. What are three indications for neuromuscular blocking agents?
Muscle relaxation during surgery, endotracheal intubation, and electroconvulsive therapy.
10. What is another name for non-depolarizing agents?
Curariform drugs
11. What is the mechanism of action for non-depolarizing neuromuscular blockers?
They bind to nicotinic receptors on motor end plates, competitively inhibit acetylcholine binding, and prevent muscle membrane depolarization.
12. What is the sequence of paralysis for non-depolarizing neuromuscular blocking agents?
Small and rapidly moving muscles (e.g., eyes and face) are affected first, followed by larger muscles of the limbs and trunk, and finally the intercostal muscles and diaphragm. Recovery occurs in reverse order.
13. What are three adverse effects of non-depolarizing neuromuscular blocking agents?
Histamine release, blockade of autonomic ganglia, and vagolytic action.
14. What four non-depolarizing neuromuscular blocking agents cause histamine release, and what are the effects and prevention methods?
Tubocurarine, mivacurium, metocurine, and atracurium. Effects include hypotension and bronchospasm. Prevention involves pre-medication with antihistamines.
15. Which two non-depolarizing neuromuscular blocking agents block autonomic ganglia, and what are the effects?
Tubocurarine and metocurine, causing hypotension and tachycardia.
Access our quiz, which includes sample TMC practice questions and detailed explanations to help you master the key concepts of pharmacology.
16. Which non-depolarizing neuromuscular blocking agent has vagolytic action, and what is its effect?
Pancuronium, which causes moderate tachycardia.
17. What are the pharmacokinetic characteristics of non-depolarizing neuromuscular blockers?
They have poor gastrointestinal absorption, are only administered intravenously, do not cross the blood-brain barrier, and are eliminated primarily unchanged in urine and bile. Some have hepatic metabolites.
18. Which non-depolarizing neuromuscular blocking agent undergoes spontaneous non-enzymatic degradation, making it suitable for patients with liver or kidney impairment?
Cisatracurium
19. What is the interaction between non-depolarizing neuromuscular blockers and cholinesterase inhibitors (e.g., neostigmine, physostigmine, pyridostigmine) and why?
Cholinesterase inhibitors attenuate muscle relaxation by increasing acetylcholine levels, helping treat overdoses of non-depolarizing blockers and promoting recovery post-surgery.
20. What allows acetylcholine to outcompete competitive inhibition at the neuromuscular junction?
Cholinesterase inhibitors
21. What is the interaction between non-depolarizing neuromuscular blockers and inhaled anesthetics (e.g., isoflurane, halothane) and why?
Inhaled anesthetics potentiate the muscle-relaxing effects of non-depolarizing blockers, necessitating a reduced dosage when used together.
22. What interaction occurs between non-depolarizing neuromuscular blockers and aminoglycoside antibiotics (e.g., gentamicin, tobramycin)?
These antibiotics suppress acetylcholine release from motor nerve terminals, enhancing muscle relaxation.
23. What is the interaction between non-depolarizing neuromuscular blockers and calcium channel blockers?
They enhance muscle-relaxing effects.
24. What four considerations should be taken into account when selecting non-depolarizing neuromuscular blocking agents?
Duration of action, relative potency, onset time for muscle relaxation, drug-induced histamine release, and cardiac effects.
25. What is the classification and mechanism of action of succinylcholine?
Succinylcholine is a depolarizing neuromuscular blocking agent that binds to nicotinic receptors on the motor end plate, depolarizes the membrane, and is resistant to acetylcholinesterase, leading to prolonged depolarization and muscle paralysis.
26. What is the sequence of paralysis for succinylcholine?
Initial brief muscle contractions (fasciculations); small, rapidly moving muscles are affected first (e.g., eyes, face); followed by larger muscles of the limbs and trunk; intercostal muscles and diaphragm are affected last; recovery occurs in the reverse order.
27. What describes the structure, administration route, and duration of action for succinylcholine?
It is a positively charged quaternary amine, making it ineffective when taken orally. It is administered via IV, typically through IV infusion, and has a short duration of action lasting approximately 5–10 minutes.
28. What is the pathway of elimination for succinylcholine and factors affecting metabolism?
Succinylcholine is hydrolyzed by plasma cholinesterase (butyrylcholinesterase). The duration of action can be influenced by cholinesterase levels, and individuals with certain genetic variants may experience prolonged action.
29. What are three major potential adverse effects of succinylcholine use?
Hyperkalemia, malignant hyperthermia, and postoperative myalgia.
30. In which four types of patients is succinylcholine contraindicated?
Patients with burns, spinal cord injuries, muscular dystrophy, and those with massive tissue injury.
31. What are the uses of neuromuscular blocking agents?
They facilitate intubation, aid in surgery, enhance ventilator synchrony, reduce intracranial pressure (ICP), lower oxygen consumption, keep patients immobile, and terminate conditions like tetanus and status epilepticus.
32. Which neurotransmitter is responsible for nerve conduction in skeletal muscle?
Acetylcholine
33. What occurs during depolarization?
Action potential generation, leading to muscle contraction.
34. What occurs during repolarization?
The membrane potential returns to baseline, resulting in muscle relaxation.
35. What are the two methods to block muscle contraction?
Competitive inhibition and prolonged occupation with persistent binding.
36. Which agents are used for competitive inhibition?
Non-depolarizing agents
37. Which agents are used for prolonged occupation and persistent binding?
Depolarizing agents
38. How do non-depolarizing agents function?
They block acetylcholine receptors on the muscle without activating them. By doing so, acetylcholine released from the axon cannot bind to its receptor sites, preventing muscle contraction.
39. What must non-depolarizing agents resemble to bind to acetylcholine receptors on muscles?
They must resemble acetylcholine in structure.
40. How must non-depolarizing agents be administered and why?
They must be given intravenously because they are poorly absorbed in the gastrointestinal tract.
41. What are the three categories of skeletal muscle relaxants?
Neuromuscular blocking agents, centrally acting muscle relaxants, and peripherally acting muscle relaxants.
42. How do neuromuscular blockers cause muscle relaxation?
They interfere with the transmission at the neuromuscular end plate.
43. What are the characteristics of neuromuscular blockers?
They are highly polar, not absorbed orally, and do not cross the blood-brain barrier. The patient remains fully conscious but is paralyzed.
44. How are neuromuscular blockers administered?
Via IV
45. What are the two pharmacological categories of neuromuscular blockers?
Non-depolarizing agents that competitively antagonize acetylcholine at the neuromuscular junction (e.g., tubocurarine) and depolarizing agents that produce a polarizing block (e.g., succinylcholine).
46. What are the depolarizing neuromuscular blockers?
Succinylcholine and decamethonium.
47. What are the long-acting non-depolarizing neuromuscular blockers?
Pancuronium, doxacurium, and pipecuronium.
48. What are the intermediate-acting non-depolarizing neuromuscular blockers?
Atracurium and vecuronium.
49. What are the pharmacological actions of neuromuscular blockers?
They act at the neuromuscular junction to block acetylcholine neurotransmission and induce paralysis, and they may cause histamine release.
50. In which condition should neuromuscular blocking agents be used with extreme caution, if at all?
Myasthenia gravis
51. What does histamine release cause?
It can lead to flushing, hypotension, excessive bronchial and salivary secretions, and bronchospasms. These effects can be mitigated with pretreatment using antihistamines but not with atropine or neostigmine.
52. What are the adverse effects of neuromuscular blockers?
Hypotension due to histamine release, bronchospasms, excessive secretions, and potential respiratory failure.
53. What drug interactions should be considered when administering neuromuscular blocking agents?
General anesthetics act synergistically with competitive blocking agents. Other interactions include quinidine, lidocaine, local anesthetics, antiarrhythmics, aminoglycoside antibiotics (e.g., gentamicin, neomycin, kanamycin), bacitracin, lincomycin, clindamycin, calcium channel blockers, furosemide, and magnesium.
54. What are the clinical uses of neuromuscular blockers?
They are used as adjuncts to surgical anesthesia to induce skeletal muscle relaxation, facilitate intubation, assist in orthopedic procedures, and reduce muscle contraction intensity during electroconvulsive therapy.
55. What are examples of non-depolarizing neuromuscular blockers?
Vecuronium bromide, pancuronium bromide, and benzylisoquinoline derivatives.
56. What is a depolarizing (non-competitive) blocking agent?
Succinylcholine
57. What is the mechanism of action of succinylcholine?
It acts by depolarizing the motor end plate similar to acetylcholine, producing transient muscle activation.
58. What does persistent depolarization caused by succinylcholine result in?
It blocks neuromuscular transmission by preventing the sub-synaptic membrane from repolarizing.
59. What do all neuromuscular blocking agents lack?
They do not possess any analgesic, sedative, or anesthetic properties.
60. What interactions can occur with succinylcholine?
Interactions can occur with carbamates, organophosphates, and other cholinesterase inhibitors.
61. What is an example of a tranquilizer that may be hazardous when used with succinylcholine?
Phenothiazine, due to its anticholinesterase activity.
62. What prolongs the action of succinylcholine?
Conditions that increase plasma potassium levels, such as burns, tetanus, or trauma.
63. What are the clinical uses of neuromuscular blocking agents?
They are used for skeletal muscle relaxation before surgery, muscle spasm relief in convulsive conditions like tetanus, prevention of dislocations and fractures during electroconvulsive therapy, and as a diagnostic aid for myasthenia gravis.
64. Why does succinylcholine have a brief duration of action?
Due to rapid hydrolysis by cholinesterase enzymes in the liver and plasma.
65. What can cause prolonged depolarization from succinylcholine?
Muscle cells may lose significant potassium, leading to elevated serum potassium levels, making it contraindicated in patients with hyperkalemia.
66. What are the cardiovascular effects of succinylcholine?
It affects all cholinoreceptors, including nicotinic receptors in the sympathetic and parasympathetic nervous systems, the adrenal medulla, and muscarinic receptors in the heart. Low doses can cause bradycardia (preventable by atropine), while large doses can result in hypertension and tachycardia due to stimulation of sympathetic ganglia and the adrenal medulla.
67. In which condition is succinylcholine contraindicated?
It is contraindicated in glaucoma due to the risk of increased intraocular and intracranial pressures.
68. What is malignant hyperthermia?
A potential adverse reaction to succinylcholine characterized by muscle rigidity, elevated body temperature, and increased metabolic rate.
69. What are the clinical uses of succinylcholine?
It is the drug of choice for endoscopy, terminating laryngospasm, facilitating endotracheal intubation, and aiding in orthopedic procedures.
70. What can be said about the potency of succinylcholine?
Its potency varies between species, with bovine and canine species being particularly sensitive.
71. What is important to know about succinylcholine preparations?
They should always be refrigerated as the drug is rapidly hydrolyzed.
72. What do neuromuscular blocking agents NOT do?
They do not cause sedation or relieve pain.
73. What is succinylcholine?
It is the most commonly used depolarizing neuromuscular blocking drug.
74. What do non-depolarizing neuromuscular blocking agents do?
They prevent acetylcholine from acting at the neuromuscular junction, thereby inhibiting skeletal muscle contraction.
75. What is a common adverse effect of non-depolarizing neuromuscular blocking agents?
Hypotension
76. What is the therapeutic use of neuromuscular blocking agents?
They are used to promote skeletal muscle relaxation and facilitate endotracheal intubation.
77. What is the most common adverse effect of neuromuscular blocking agents?
Hypotension, often due to histamine release.
78. What is the dosage range of succinylcholine for pediatric patients?
1-3 mg/kg
79. What is the dosage range of succinylcholine for adult patients?
0.3-1.1 mg/kg
80. What are the side effects associated with succinylcholine?
Hypokalemia and increased intraocular pressure.
81. What are the steps leading to neuromuscular transmission?
Nerve stimulation; action potential; release of acetylcholine (Ach); activation of nicotinic receptors on the post-junctional membrane; opening of the ion channel in the nicotinic receptor; and depolarization, leading to end-plate potential in the muscle.
82. Why is desensitization of nicotinic receptors important?
Nicotinic receptors can become desensitized when exposed to continuous levels of Ach or other nicotinic agents. During desensitization, the receptor undergoes a conformational change to a non-conducting state and cannot be reactivated until the agonist unbinds and the receptor returns to its resting state.
83. What is the mechanism of action for competitive neuromuscular blocking agents?
These agents bind to nicotinic receptors on the post-junctional membrane, blocking Ach from accessing these sites.
84. How can the effects of competitive neuromuscular blockers be reversed?
By increasing the concentration of Ach at the NMJ; anticholinesterase drugs such as neostigmine can be used to reverse the effects of competitive blockers.
85. Why are neuromuscular blocking agents particularly dangerous for patients with myasthenia gravis?
Patients with myasthenia gravis have a reduced number of functional nicotinic receptors, making them extremely sensitive to neuromuscular blockers, which can significantly worsen their condition.
86. What is the mechanism of action for depolarizing neuromuscular blockers?
These agents activate nicotinic receptors and depolarize the post-junctional membrane in the same manner as Ach, but in a more prolonged manner, leading to persistent depolarization.
87. What is the effect of anticholinesterase drugs on depolarizing neuromuscular blockers?
They do not reverse the effects of depolarizing blockers; in fact, by increasing levels of Ach at the NMJ, they may enhance the blockade.
88. What type of drug is succinylcholine?
A depolarizing neuromuscular blocker.
89. Is a patient conscious when given a neuromuscular blocking agent?
Yes, the patient remains fully conscious; therefore, general anesthetics and analgesics must be co-administered.
90. How do neuromuscular blocking drugs exert their effects?
They alter the action at post-synaptic acetylcholine receptors, ultimately resulting in paralysis.
91. What are the considerations for administering neuromuscular blocking agents in patients with hepatic or renal impairment?
Certain non-depolarizing agents may be affected due to their dependence on hepatic or renal elimination, so agents like cisatracurium, which undergo spontaneous degradation, are preferred.
92. What is the significance of monitoring train-of-four (TOF) in patients receiving neuromuscular blockers?
TOF monitoring helps assess the degree of neuromuscular blockade and ensures proper dosing to avoid prolonged paralysis.
93. What are the main side effects of non-depolarizing neuromuscular blockers?
Potential side effects include histamine release causing hypotension and bronchospasm, tachycardia, and prolonged muscle weakness.
94. Why must succinylcholine be used cautiously in patients with hyperkalemia?
Succinylcholine can cause potassium release from muscle cells, exacerbating hyperkalemia and potentially leading to life-threatening cardiac arrhythmias.
95. What is a contraindication for using succinylcholine in pediatric patients?
Succinylcholine is contraindicated in pediatric patients with undiagnosed neuromuscular diseases due to the risk of severe hyperkalemia and cardiac arrest.
96. How do non-depolarizing agents differ from depolarizing agents in their mechanism of action?
Non-depolarizing agents block nicotinic receptors without activating them, preventing depolarization, while depolarizing agents like succinylcholine activate receptors and cause continuous depolarization until desensitization occurs.
97. What is the duration of action for long-acting non-depolarizing neuromuscular blockers?
Typically over 60 minutes, as seen with agents like pancuronium and doxacurium.
98. What are the steps involved in reversing the effects of non-depolarizing neuromuscular blockers?
Administration of anticholinesterase drugs (e.g., neostigmine) to increase Ach levels at the NMJ, often paired with anticholinergic agents to prevent muscarinic side effects.
99. What is the indication for the use of sugammadex?
Sugammadex is used to reverse the effects of certain non-depolarizing neuromuscular blockers, such as rocuronium and vecuronium, by encapsulating the drug and facilitating its elimination.
100. What is the significance of ensuring proper ventilation when using neuromuscular blockers?
Patients may experience complete paralysis of respiratory muscles, so mechanical ventilation is necessary to maintain adequate oxygenation and ventilation until the drug effect wears off.
Final Thoughts
Neuromuscular blocking agents are indispensable in modern medical practice, providing clinicians with the means to achieve targeted muscle relaxation and optimize procedural conditions.
However, the use of these agents requires a comprehensive understanding of their mechanisms, potential side effects, and appropriate reversal strategies to ensure patient safety.
For medical professionals and students, mastering the application of NMBAs is a critical step in delivering effective and safe care during procedures requiring temporary paralysis.
Written by:
John Landry is a registered respiratory therapist from Memphis, TN, and has a bachelor's degree in kinesiology. He enjoys using evidence-based research to help others breathe easier and live a healthier life.
References
- Adeyinka A, Layer DA. Neuromuscular Blocking Agents. [Updated 2024 Jun 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.